西南医科大学学报2024，Vol.47Issue(4)：283-288,6.DOI:10.3969/j.issn.2096-3351.2024.04.002
胶质母细胞瘤治疗现状和困境
Current state and dilemma of glioblastoma treatment
摘要
Abstract
Glioblastoma(GBM)is the most common primary intracranial malignant tumor,standing with treatment prospective and poor prognosis.GBM is treated with a comprehensive treatment regimen including surgery,radiotherapy,and chemotherapy.The me-dian survival for GBM is only 14.6 months,and for recurrence,it is no more than 8 months.New therapies such as targeted therapy,elec-tric field therapy,oncolytic viruses,cell therapy,and tumor vaccines are emerging,which prolong the survival of GBM.Due to the high degree of malignancy,high degree of heterogeneity,immunosuppressive microenvironment,poor response to radiotherapy and chemo-therapy,the therapeutic effect has not met the expectation.This article analyzed and reviewed the traditional and emerging treatments for GBM,and analyzed their advantages and disadvantages,in order to provide references and ideas for GBM treatment program selec-tion and design,as well as new drugs,new strategies,new instruments and equipments.关键词
胶质母细胞瘤/手术/放疗/化疗/免疫治疗/肿瘤微环境Key words
Glioblastoma/Surgery/Radiotherapy/Chemotherapy/Immunotherapy/Tumor microenvironment分类
医药卫生引用本文复制引用
刘泓渊,曾辉,李宗平,周良学..胶质母细胞瘤治疗现状和困境[J].西南医科大学学报,2024,47(4):283-288,6.基金项目
国家自然科学基金(81772693) （81772693）
科技部"十三五""重大新药创制"国家科技重大专项(2019ZX09301-147) （2019ZX09301-147）
